<DOC>
	<DOCNO>NCT00454246</DOCNO>
	<brief_summary>This study ass efficacy safety methoxy polyethylene glycol-epoetin beta ( Mircera ) maintenance hemoglobin level patient previously receive treatment epoetin alfa darbepoetin alfa , transition chronic kidney disease stage 4 dialysis . Patients randomize either receive Mircera remain exist therapy ; initial monthly dose subcutaneous ( sc ) Mircera ( 120-360 microgram ) base average weekly dose epoetin alfa darbepoetin alfa administer week precede switch Mircera . At initiation dialysis , patient Mircera group receive monthly intravenous ( iv ) Mircera start dose base previous ( sc ) dose , control group receive weekly ( iv ) epoetin alfa . The anticipated time study treatment 1-2 year , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Mircera Hemoglobin Control Patients Transitioning Dialysis .</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic kidney disease stage IV require dialysis ; expect initiate dialysis within 18 month ; 15 &lt; =Glomerular Filtration Rate ( GFR ) &lt; =29 . fail renal allograft place ; acute chronic bleeding within 8 week prior screen ; transfusion red blood cell within 8 week prior screen ; poorly control hypertension ; immunosuppressive therapy 12 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>